1
Orphan Designations
0 approved, 1 designated
0
FDA Approvals
2
Active Trials
96 recruiting
2
Rare Diseases
across 8 areas
0
News (30d)
Quiet
Pasithea Therapeutics Corp. is a company with 1 orphan drug designation across 2 rare diseases. Active clinical trials in 2 indications. 2 active policy bills affect their portfolio.
Disease-by-disease pipeline progression from orphan designation through clinical trials to FDA approval.
Source: FDA Orphan Drug Designations, ClinicalTrials.gov, Drugs@FDA
| Disease | Drug(s) | Stage |
|---|---|---|
| neurofibromatosis | - | Des.TrialAppr. |
| neurofibromatosis type 1 | allosteric MEK 1/2 inhibitor | Des.TrialAppr. |
0% of portfolio targets high unmet need diseases
9
overlap in 2+ diseases
0/2
candidate diseases
0
avg importance: 0
2
affecting portfolio
0% of portfolio targets high unmet need diseases
9
overlap in 2+ diseases
0/2
candidate diseases
0
avg importance: 0
2
affecting portfolio